News

GSK plc announced that ViiV Healthcare has reported positive 12-month interim results from its phase IIb EMBRACE study, highlighting the potential of an ultra long-acting HIV treatment…
Read More...

GSK plc has agreed to acquire 35Pharma Inc., a privately held Canadian biopharmaceutical company focused on protein-based therapeutics. The deal brings into GSK’s pipeline HS235, an…
Read More...

Gilead Sciences, Inc. has entered into a definitive agreement to acquire Arcellx in a transaction valued at approximately $7.8 billion, strengthening its oncology and cell therapy…
Read More...

AbbVie has unveiled plans to invest $380 million to construct two new active pharmaceutical ingredient (API) manufacturing facilities at its North Chicago, Illinois campus, expanding…
Read More...

The U.S. Food and Drug Administration has released a new draft guidance aimed at accelerating the development and approval of highly targeted, individualized therapies for patients with…
Read More...

AstraZeneca has secured U.S. approval for a new all-oral, fixed-duration treatment regimen for adults with chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL),…
Read More...

The European Commission has announced a €225 million investment aimed at accelerating the development of next-generation influenza vaccines capable of providing broader protection…
Read More...

AbbVie has announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for the combination of VENCLEXTA® (venetoclax) and acalabrutinib…
Read More...

Clinical-stage biotech VivaMed BioPharma has entered into a strategic partnership with Syngene International, a global contract research, development and manufacturing organization…
Read More...

Merck & Co., Inc., known as MSD outside the United States and Canada, has entered into a major research and development agreement with Mayo Clinic to apply artificial intelligence…
Read More...

Novartis has announced positive topline results from its pivotal Phase III RemIND trial evaluating oral remibrutinib in patients with chronic inducible urticaria (CIndU), a condition…
Read More...

Johnson & Johnson has unveiled new data from its Phase 1b/2 OrigAMI-4 study, demonstrating that first-line treatment with investigational subcutaneous amivantamab and…
Read More...

Boehringer Ingelheim India Private Limited has signed a Memorandum of Understanding (MoU) with National Institute of Pharmaceutical Education and Research, Raebareli (NIPER Raebareli),…
Read More...

Catalent and S.Biomedics have entered into a strategic partnership to advance the development and manufacturing of TED-A9, an investigational allogeneic pluripotent stem cell-derived…
Read More...

Johnson & Johnson has announced plans to invest more than $1 billion in a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania, further…
Read More...

Unnatural Products, Inc. (UNP), a biotechnology company focused on developing orally delivered macrocyclic peptides for hard-to-drug targets, has entered into a research collaboration…
Read More...

Scribe Therapeutics, Inc. has achieved a second success milestone in its ongoing collaboration with Eli Lilly and Company, marking further progress in the development of in vivo…
Read More...

Teijin Pharma Limited has signed a joint research agreement with Aska Pharmaceutical Co., Ltd. to develop new small-molecule drug candidates for gynecological diseases, marking a…
Read More...

Immunic, Inc. announced it has priced a private placement expected to generate up to $400 million in gross proceeds, funding the company’s shift from a research-focused biotech to a…
Read More...

Disc Medicine said the U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) for its New Drug Application seeking approval of bitopertin to treat erythropoietic…
Read More...